Selected article for: "CAL group group and IVIG resistance"

Author: Kang, Soo Jung; Kim, Nam Su
Title: Association of Toll-like receptor 2-positive monocytes with coronary artery lesions and treatment nonresponse in Kawasaki disease
  • Document date: 2017_7_31
  • ID: tk1bxztw_47
    Snippet: Our results showed that FTLR2% before the initial treatment is a more sensitive predictor of CAL development than sIL10 in patients with KD. sIL10 before treatment was shown to be elevated in pati ents with acutestage KD, and its cutoff values for the prediction of CAL development and IVIG resistance have been previously proposed 27) . We found that sIL10 before treatment in the CAL (+) group was not significantly higher than that in the CAL () g.....
    Document: Our results showed that FTLR2% before the initial treatment is a more sensitive predictor of CAL development than sIL10 in patients with KD. sIL10 before treatment was shown to be elevated in pati ents with acutestage KD, and its cutoff values for the prediction of CAL development and IVIG resistance have been previously proposed 27) . We found that sIL10 before treatment in the CAL (+) group was not significantly higher than that in the CAL () group. The reason for this finding might be that, in our study, patients be longing to the CAL (+) group were those that had developed CALs at one month after diagnosis. High sIL10 at the acute stage of KD might have had a cumulative beneficial effect on the inflammation of the coronaries past the acute stage of KD, as IL10 is known to have both antiinflammatory and proinflammatory properties 19, 20) .

    Search related documents:
    Co phrase search for related documents
    • cutoff value and IVIG resistance: 1, 2
    • cutoff value and IVIG resistance CAL development: 1
    • initial treatment and IVIG resistance: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • initial treatment and IVIG resistance CAL development: 1, 2, 3
    • initial treatment and treatment sIL10: 1, 2, 3, 4
    • IVIG resistance and KD acute stage: 1, 2
    • IVIG resistance and KD patient: 1
    • IVIG resistance and treatment sIL10: 1, 2
    • IVIG resistance CAL development and treatment sIL10: 1, 2